- Home
- ZH vs MAZE Comparison
ZH vs MAZE Comparison
Compare ZH & MAZE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZH
- MAZE
- Stock Information
- Founded
- ZH 2011
- MAZE 2018
- Country
- ZH China
- MAZE United States
- Employees
- ZH N/A
- MAZE N/A
- Industry
- ZH Business Services
- MAZE
- Sector
- ZH Consumer Discretionary
- MAZE
- Exchange
- ZH Nasdaq
- MAZE NYSE
- Market Cap
- ZH 353.6M
- MAZE 367.0M
- IPO Year
- ZH 2021
- MAZE 2025
- Fundamental
- Price
- ZH $4.01
- MAZE $12.93
- Analyst Decision
- ZH Strong Buy
- MAZE Strong Buy
- Analyst Count
- ZH 1
- MAZE 3
- Target Price
- ZH $4.70
- MAZE $25.67
- AVG Volume (30 Days)
- ZH 172.9K
- MAZE 94.2K
- Earning Date
- ZH 05-27-2025
- MAZE 05-14-2025
- Dividend Yield
- ZH N/A
- MAZE N/A
- EPS Growth
- ZH N/A
- MAZE N/A
- EPS
- ZH N/A
- MAZE 0.34
- Revenue
- ZH $464,095,225.00
- MAZE $167,500,000.00
- Revenue This Year
- ZH N/A
- MAZE N/A
- Revenue Next Year
- ZH $7.46
- MAZE N/A
- P/E Ratio
- ZH N/A
- MAZE $38.42
- Revenue Growth
- ZH N/A
- MAZE N/A
- 52 Week Low
- ZH $2.55
- MAZE $6.71
- 52 Week High
- ZH $6.32
- MAZE $17.00
- Technical
- Relative Strength Index (RSI)
- ZH 53.05
- MAZE N/A
- Support Level
- ZH $3.74
- MAZE N/A
- Resistance Level
- ZH $4.22
- MAZE N/A
- Average True Range (ATR)
- ZH 0.15
- MAZE 0.00
- MACD
- ZH 0.01
- MAZE 0.00
- Stochastic Oscillator
- ZH 56.61
- MAZE 0.00
About ZH Zhihu Inc. (every two of each representing one ordinary share)
Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.
About MAZE MAZE THERAPEUTICS INC
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.